Prospera Private Wealth LLC Buys 602 Shares of Sanofi (NASDAQ:SNY)

Prospera Private Wealth LLC boosted its stake in Sanofi (NASDAQ:SNY) by 3.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,467 shares of the company’s stock after purchasing an additional 602 shares during the quarter. Prospera Private Wealth LLC’s holdings in Sanofi were worth $1,064,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Blair William & Co. IL purchased a new position in shares of Sanofi in the first quarter valued at $204,000. Clearbridge Investments LLC raised its position in Sanofi by 3.2% during the first quarter. Clearbridge Investments LLC now owns 172,214 shares of the company’s stock valued at $8,370,000 after purchasing an additional 5,411 shares during the period. Lake Street Advisors Group LLC lifted its stake in shares of Sanofi by 24.8% in the 1st quarter. Lake Street Advisors Group LLC now owns 7,174 shares of the company’s stock valued at $349,000 after purchasing an additional 1,426 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Sanofi by 3.5% in the 1st quarter. National Bank of Canada FI now owns 350,895 shares of the company’s stock worth $17,281,000 after purchasing an additional 11,996 shares during the period. Finally, Pitcairn Co. bought a new stake in Sanofi in the first quarter worth $273,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Sanofi stock opened at $48.00 on Wednesday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a market capitalization of $121.82 billion, a PE ratio of 24.49, a P/E/G ratio of 1.22 and a beta of 0.61. The company has a 50 day moving average price of $54.25 and a 200-day moving average price of $52.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the business earned $2.55 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 4.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus boosted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.